Electromed, Inc. Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures and markets airway-clearance products using High Frequency Chest Wall Oscillation therapy, including the SmartVest System. Products are sold to home-care and institutional customers in the United States and internationally. This unaudited report covers the three and six months ended December 31, 2015, the second quarter and first six months of fiscal 2016.
Financial Performance and Position
| Metric | Three Months Ended Dec. 31, 2015 | Year-over-Year Change | Six Months Ended Dec. 31, 2015 | Year-over-Year Change |
|---|---|---|---|---|
| Net revenue | $6.262 million | +28.3% | $11.263 million | +16.7% |
| Gross profit | $4.899 million | +43.9% | $8.758 million | +30.8% |
| Gross margin | 78.2% | 69.7% prior year | 77.8% | 69.4% prior year |
| Operating income | $1.250 million | +179.6% | $1.835 million | +117.0% |
| Net income | $1.068 million | +152.6% | $1.409 million | +76.0% |
| Diluted EPS | $0.13 | $0.05 prior year | $0.17 | $0.10 prior year |
- Revenue mix for the six-month period was $9.987 million home care, $924,000 institutional and $352,000 international.
- SG&A increased 25.1% for the quarter and 19.9% year to date, primarily from additional sales and support employees, compensation, commissions, bonuses, consulting and travel.
- Research and development expense declined to $57,000 for the quarter and $99,000 year to date as major SmartVest SQL manufacturing-cost-reduction projects were substantially completed.
- Income tax expense was $164,000 for the quarter and $388,000 year to date, compared with no tax expense in the prior-year periods. The company released its full valuation allowance against U.S. deferred tax assets, recognizing approximately $288,000 of net deferred tax assets and a related discrete tax benefit.
- Cash was $4.529 million at December 31, 2015, compared with $3.598 million at June 30, 2015. Total current assets were $14.167 million and current liabilities were $2.430 million.
- Six-month operating cash flow was $1.167 million, compared with $1.324 million in the prior-year period. Investing cash outflow was $199,000, and financing cash outflow was $38,000.
- Total debt was approximately $1.227 million, consisting principally of a term loan; the balance-sheet presentation included $48,774 of current maturities and $1.178 million of long-term debt.
Material Changes Versus the Prior Comparable Period
- Home-care revenue increased 21.5% in the quarter and 17.2% year to date, driven by improved third-party-payer approvals, faster approval cycles, new payer contracts and higher average selling prices. The quarter also benefited from approximately $250,000 of revenue from prior-period referrals processed after a state license was reinstated.
- Institutional revenue increased 69.0% in the quarter and 34.1% year to date, primarily because several customers purchased multiple units.
- International revenue increased sharply in the quarter but declined 19.8% year to date because the prior year included distributor purchases pulled forward ahead of European Union RoHS 2 compliance. The company resumed shipments to European Union distributors after becoming compliant in the second half of fiscal 2015.
- Gross margin expanded materially because of a greater proportion of domestic home-care revenue, improved approval rates and average selling prices, and lower SmartVest SQL manufacturing costs.
- Net income benefited from both operating improvement and the $288,000 deferred-tax valuation-allowance release.
- The company early adopted the new deferred-tax balance-sheet classification guidance prospectively. It also disclosed future adoption of revenue-recognition, debt-issuance-cost and inventory-measurement standards; expected impacts were not yet determined.
Guidance, Outlook, Risks and Unusual Items
- Management stated that working capital of approximately $11.7 million and available credit-facility borrowings should provide adequate liquidity for the next year based on current operating performance.
- Management expects research and development spending as a percentage of revenue to increase over the next twelve months for product enhancements and other market opportunities.
- The medical-device excise tax was subject to a two-year moratorium beginning January 1, 2016, which management expected to improve operating profit.
- The $2.5 million revolving credit line was renewed through December 18, 2016, subject to borrowing-base limitations. No amount was outstanding, and the full $2.5 million was eligible at December 31, 2015. The term loan bears interest at 5.00% and has a final payment of approximately $1.090 million due December 18, 2018.
- Debt agreements require minimum tangible net worth of $10.125 million and impose restrictions on additional indebtedness and dividends. The company was in compliance at December 31, 2015. Noncompliance could trigger acceleration, restrict borrowing or prevent renewal of the revolving line.
- Key risks include reimbursement and healthcare-law changes, regulatory compliance and approvals, international-market expansion, competition, intellectual-property protection, credit renewal and general economic conditions.
- The company provides lifetime warranties for prescribed U.S. patients and three-year warranties for institutional and non-U.S. sales. The warranty reserve was $640,000 at December 31, 2015.
- The filing states that ordinary-course claims and disputes may arise, including intellectual-property claims, but that no undisclosed litigation was expected to have a material adverse effect. No off-balance-sheet arrangements were reported.
Important Facts for Investors to Verify
- Whether higher home-care reimbursement approvals, average selling prices and margins are sustainable after the benefit from backlog referrals.
- The extent to which institutional and international revenue will fluctuate with customer and distributor purchasing timing.
- The recurring versus discrete components of the reported tax rate and the sustainability of deferred-tax-asset realization.
- Compliance with the $10.125 million tangible-net-worth covenant and renewal of the revolving line before December 18, 2016.
- Future warranty claims, inventory-obsolescence exposure and the effect of increased sales-force and research-and-development spending on cash flow.
- Management’s forward-looking assumptions regarding SmartVest SQL adoption, international growth, reimbursement policy and long-term margins.